Media & Resources
Engage with the leading edge of biopharmaceuticals

Press Release

Bexion Pharmaceuticals Announces Issuance of Japanese Patent

Novel Nanotechnology for Cancer

Bexion Pharmaceuticals and Cincinnati Children’s Hospital Medical Center (CCHMC) are pleased to announce that the Japanese Patent Office has issued a Decision to Grant a Letters Patent for the application entitled, “Saposin C-DOPS: A Novel Anti-Tumor Agent”.

This proprietary technology is manifested in Bexion’s BXQ-350. Bexion is developing BXQ-350 nanovesicles as a potential treatment for glioblastoma multiforme, the deadliest form of brain cancer. BXQ-350 nanovesicles have an affinity for the membrane patches that are common in many types of tumor cells including glioblastoma cells. Bexion's studies have shown effectiveness in the laboratory in multiple animal tumor models, and across a remarkable range of tumors in cell culture. The recently issued Japanese Patent number 4762132 is assigned to Cincinnati Children’s Hospital and licensed to Bexion Pharmaceuticals, to which Bexion has exclusive rights in the US and major international markets.

“This patent is an important component of our intellectual property portfolio for protecting our innovative approach for cancer therapy,” stated Bexion co-founder and CEO, Dr. Ray Takigiku.

"This important patent will help in advancing Bexion's development of SapC-DOPS as a cancer therapy, and it also opens up the door for future collaborations in Japan on this groundbreaking technology," stated Dr. Niki Robinson, Assistant Vice President, Center for Technology Commercialization, CCHMC.

About Bexion Pharmaceuticals

Bexion Pharmaceuticals is focused on the development and commercialization of innovative cures for cancer. Initial products are based on a patent-protected and proprietary platform technology licensed from Cincinnati Children's Hospital Medical Center. The technology has demonstrated potential for development as therapeutics, diagnostics and surgical imaging reagents, as well as carriers for other pharmaceutical agents, such as oligonucleotides. For more information, visit www.bexionpharma.com.

Media Contact

Margaret van Gilse
VP, Business Development
Bexion Pharmaceuticals, LLC
632 Russell Street
Covington, KY 41011
Phone: (513) 833-7065
mvangilse@bexionpharma.com

Investor Enquiries

Chuck Scheper
Chair
Bexion Pharmaceuticals, LLC
632 Russell Street
Covington, KY 41011
Phone: (513) 252-2169
cscheper@bexionpharma.com